Search results
Showing 1186 to 1200 of 7680 results
Evidence-based recommendations on quizartinib (Vanflyta) for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia in adults.
Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)
Evidence-based recommendations on tepotinib (Tepmetko) for treating advanced non-small-cell lung cancer (NSCLC) with MET gene alterations in adults.
NICE is unable to make a recommendation on TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices because Medtronic withdrew its evidence submission.
Show all sections
Sections for TA790
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) (TA782)
NICE is unable to make a recommendation on tagraxofusp (Elzonris) for treating blastic plasmacytoid dendritic cell neoplasm. This is because Stemline Therapeutics did not provide an evidence submission.
Show all sections
Sections for TA782
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.
Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
NICE is unable to make a recommendation on nivolumab (Opdivo) with cabozantinib for untreated advanced renal cell carcinoma. This is because Bristol Myers Squibb withdrew the evidence submission.
Show all sections
Sections for TA785
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease (TA20)
Evidence-based recommendations on the use of riluzole (Rilutek) for treating motor neurone disease (MND).